- Home
- ACLS vs IMCR Comparison
ACLS vs IMCR Comparison
Compare ACLS & IMCR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ACLS
- IMCR
- Stock Information
- Founded
- ACLS 1995
- IMCR 2008
- Country
- ACLS United States
- IMCR United Kingdom
- Employees
- ACLS N/A
- IMCR N/A
- Industry
- ACLS Industrial Machinery/Components
- IMCR Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- ACLS Technology
- IMCR Health Care
- Exchange
- ACLS Nasdaq
- IMCR Nasdaq
- Market Cap
- ACLS 2.2B
- IMCR 1.8B
- IPO Year
- ACLS 2000
- IMCR 2021
- Fundamental
- Price
- ACLS $80.04
- IMCR $32.20
- Analyst Decision
- ACLS Buy
- IMCR Buy
- Analyst Count
- ACLS 5
- IMCR 9
- Target Price
- ACLS $90.00
- IMCR $57.00
- AVG Volume (30 Days)
- ACLS 563.4K
- IMCR 304.8K
- Earning Date
- ACLS 08-05-2025
- IMCR 08-07-2025
- Dividend Yield
- ACLS N/A
- IMCR N/A
- EPS Growth
- ACLS N/A
- IMCR N/A
- EPS
- ACLS 4.91
- IMCR N/A
- Revenue
- ACLS $896,089,000.00
- IMCR $356,145,000.00
- Revenue This Year
- ACLS N/A
- IMCR $31.83
- Revenue Next Year
- ACLS $5.27
- IMCR $8.50
- P/E Ratio
- ACLS $16.31
- IMCR N/A
- Revenue Growth
- ACLS N/A
- IMCR 26.78
- 52 Week Low
- ACLS $40.40
- IMCR $23.15
- 52 Week High
- ACLS $113.37
- IMCR $39.33
- Technical
- Relative Strength Index (RSI)
- ACLS 54.35
- IMCR 42.91
- Support Level
- ACLS $79.78
- IMCR $31.98
- Resistance Level
- ACLS $82.77
- IMCR $33.08
- Average True Range (ATR)
- ACLS 2.71
- IMCR 1.07
- MACD
- ACLS -0.26
- IMCR 0.04
- Stochastic Oscillator
- ACLS 30.19
- IMCR 47.20
About ACLS Axcelis Technologies Inc.
Axcelis Technologies Inc designs, manufactures, and services ion implantation and other processing equipment used in the fabrication of semiconductor chips. In addition to equipment, the company provides aftermarket lifecycle products and services, including used tools, spare parts, equipment upgrades, maintenance services, and customer training. Geographically, the group has a business presence in North America, Asia Pacific, and Europe, of which key revenue is derived from the Asia Pacific.
About IMCR Immunocore Holdings plc
Immunocore Holdings PLC is a commercial-stage biotechnology company. Using its ImmTAX platform, the company is developing a deep pipeline in multiple therapeutic areas, including clinical stage programs in oncology and infectious disease, pre-clinical programs in autoimmune disease, and earlier pre-clinical programs across three therapeutic areas. The company's main product, KIMMTRAK, is used for the treatment of unresectable or metastatic uveal melanoma (mUM). The other drug candidates in its pipeline include Brenetafusp, IMC-P115C, IMC-T119C, IMC-R117C, IMC-S118AI, IMC-U120AI, and others, being developed as a potential treatment for various oncology, infectious, and autoimmune diseases.